10.1016/j.anireprosci.2016.03.009 17 CaiH.QinD.PengS
Neuropharmacology 111 , 160168 (2016)
But as demand grows, the conversation is expanding to address the question of scale: How can personalized medicine be delivered to every patient and provider who needs it without compromising quality, safety, or consistency
doi:10.1016/j.amjoto.2019.03.017
Key Agents and Pharmacological Profiles: Since the first GLP-1 analog was approved in 2005, multiple agents have been developed, varying in structure, receptor selectivity, dosing frequency, and clinical applications
of the plasma concentrations in the three cohorts (excluding poorly/non-compliant patients), we computed that the sample size in the smallest cohort ( n =77, Leb) would already provide 92.9% power in the analyses